Short answer
GeneDx Holdings Corp. (WGS) filed its Q3 2025 10-Q quarterly report on Oct 28, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $117M (up 51.9% year over year) with net income of −$8M.
Q3 2025 key financials · XBRL
- Revenue
- $117M
- +51.9% YoY · +13.7% QoQ
- Net income
- −$8M
- +8.1% YoY · −170.6% QoQ
- Operating margin
- -2.8%
- Gross margin
- 72.4%
- EPS (diluted)
- −$0.26
- +10.3% YoY · −170.3% QoQ
Source: XBRL data from the GeneDx Holdings Corp. (WGS) Q3 2025 10-Q on SEC EDGAR. USD.
GeneDx Holdings Corp. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: FDA final rule on lab-developed tests (LDTs) overturned March 31, 2025, creates ongoing uncertainty for LDT compliance
- Most material regulatory update: Potential enforcement of FDA oversight on LDTs could increase costs and reduce revenue, impacting financial condition
- Legal risk: Multiple lawsuits filed challenging FDA's LDT authority; U.S. District Court struck down 2024 FDA final rule, FDA did not appeal
- Operational risk: Breakthrough Device Designation for ExomeDx and GenomeDx tests in Oct 2025 may not accelerate FDA authorization or approval process
- Financial risk: Regulatory changes could increase compliance costs and delay test market entry, affecting near-term revenue and profitability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GeneDx Holdings Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.